Cargando…
Safety of the second dose of the ChAdOx1 nCoV‐19 vaccine in people with persistent anti–platelet factor 4 antibodies
Autores principales: | Uaprasert, Noppacharn, Trithiphen, Sasinipa, Sukperm, Autcharaporn, Akkawat, Benjaporn, Watanaboonyongcharoen, Phandee, Vichitratchaneekorn, Rattaporn, Tongbai, Thanisa, Jantarabenjakul, Watsamon, Paitoonpong, Leilani, Rojnuckarin, Ponlapat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606026/ https://www.ncbi.nlm.nih.gov/pubmed/34849450 http://dx.doi.org/10.1002/rth2.12625 |
Ejemplares similares
-
Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D‐dimer elevation in Thai people After ChAdOx1 nCoV‐19 vaccination
por: Uaprasert, Noppacharn, et al.
Publicado: (2021) -
Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a
Tertiary Care Center
por: Moonla, Chatphatai, et al.
Publicado: (2019) -
Cold agglutinin disease following SARS‐CoV‐2 and Mycoplasma pneumoniae co‐infections
por: Moonla, Chatphatai, et al.
Publicado: (2020) -
Prognostic factors and impact of CMV reactivation on acute myeloid leukemia patients after HLA-matched myeloablative allogeneic stem cell transplantation in a high CMV prevalence country
por: Chanswangphuwana, Chantiya, et al.
Publicado: (2023) -
Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials
por: Uaprasert, Noppacharn, et al.
Publicado: (2021)